Core Insights - McKesson reported revenue of $90.82 billion for the quarter ended March 2025, reflecting a 19% increase year-over-year, with EPS at $10.12 compared to $6.18 in the same quarter last year [1] - The revenue fell short of the Zacks Consensus Estimate of $93.7 billion by 3.08%, while the EPS exceeded the consensus estimate of $9.81 by 3.16% [1] Revenue Breakdown - U.S. Pharmaceutical revenue was $83.17 billion, a 20.9% increase year-over-year, but below the average estimate of $85.79 billion [4] - Prescription Technology Solutions revenue reached $1.34 billion, up 13.5% year-over-year, slightly below the average estimate of $1.36 billion [4] - International revenue was $3.46 billion, showing a year-over-year decline of 2.5%, compared to the average estimate of $3.55 billion [4] - Medical-Surgical Solutions revenue was $2.85 billion, a 0.6% increase year-over-year, exceeding the average estimate of $2.79 billion [4] Adjusted Operating Profit - Adjusted Operating Profit for U.S. Pharmaceutical was $1.05 billion, matching the average estimate [4] - Adjusted Operating Profit for International was $102 million, surpassing the average estimate of $96.42 million [4] - Adjusted Operating Profit for Corporate was -$165 million, slightly worse than the average estimate of -$160.18 million [4] - Adjusted Operating Profit for Prescription Technology Solutions was $285 million, exceeding the average estimate of $267.80 million [4] - Adjusted Operating Profit for Medical-Surgical Solutions was $285 million, slightly above the average estimate of $283.33 million [4] Stock Performance - McKesson's shares returned +7.5% over the past month, underperforming compared to the Zacks S&P 500 composite's +11.3% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Financial Data and Key Metrics Changes - The company reported a full year consolidated revenue growth of 16%, reaching a record level of $359 billion, with adjusted earnings per diluted share at $33.5, exceeding expectations and reflecting a year-over-year EPS growth of 20% [5][40][42] - Fourth quarter earnings per diluted share increased 64% to $10.12, driven by a lower effective tax rate and strong operational growth across the business [32][29] - Operating profit for the full year increased 15% to $5.6 billion, with significant contributions from the U.S. Pharmaceutical and Prescription Technology Solutions segments [41][42] Business Line Data and Key Metrics Changes - The U.S. Pharmaceutical segment saw revenues increase by 21% to $83.2 billion, driven by increased prescription volumes and growth in specialty product distribution [33][22] - The Prescription Technology Solutions segment reported a revenue increase of 13% to $1.3 billion, with operating profit rising 34% to $285 million, reflecting increased prescription transaction volumes [34][35] - The Medical Surgical Solutions segment experienced a 1% revenue increase to $2.9 billion, with operating profit up 15% to $285 million, benefiting from cost optimization initiatives [37][36] Market Data and Key Metrics Changes - The Canadian business, part of the international segment, reported revenues of $3.5 billion, a decrease of 2% due to the divestiture of certain businesses, but operating profit increased by 9% [38][24] - The company anticipates continued growth in the Canadian distribution business, partially offset by the impact of previous divestitures [58] Company Strategy and Development Direction - The company is focusing on strategic acquisitions in oncology and biopharma services, including the acquisition of a controlling interest in Prism Vision and Core Ventures, aimed at enhancing community-based care [6][12][49] - A strategic decision was made to separate the Medical Surgical segment into an independent company to enhance operational focus and capital deployment [19][27] - The company plans to continue investing in technology, automation, and AI to improve operational efficiencies and customer service [7][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to maintain momentum and deliver strong results in fiscal 2026, with anticipated revenue growth of 11% to 15% and operating profit growth of 8% to 12% [43][44] - The company remains committed to maximizing shareholder value through disciplined portfolio management and strategic capital deployment [27][62] Other Important Information - The company returned $3.5 billion to shareholders in fiscal 2025, including $3.1 billion through share repurchases [42] - Free cash flow for the fourth quarter was robust at $7.5 billion, driven by strong operating results [39] Q&A Session Summary Question: Impact of Medicare Part B on ASPs - Management indicated that there are currently no concrete announcements regarding Medicare Part B impacts, and any potential changes would likely face legal challenges [65][66] Question: Tariff Impacts on Business - Management is closely monitoring the tariff landscape and believes that current assessments have been incorporated into guidance, with no material impact anticipated on fiscal 2026 results [75][81] Question: Urgency in Capital Deployment for Biopharma Services - Management stated that the urgency for capital deployment remains consistent, driven by strategic alignment and financial discipline [85][88] Question: Long-term Pharma Growth Rate Guidance - Management noted that the increase in long-term guidance reflects a stable environment for prescription utilization and successful capital deployment in oncology and other specialties [92][96]

McKesson Corporation Fiscal 2025 Financial Results Fiscal 2026 Outlook May 8, 2025 Cautionary Statements Cautionary Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward- looking statements may be identified by their use of terminology such as "believes," "expects," "anticipates," "may," "will," "should," "seeks," "approximately," "intends," "projects," "plans," "estimat ...

Core Insights - Wellgistics Health, Inc. is launching an initiative to utilize XRP as a treasury reserve and real-time payments infrastructure, aiming to be among the first publicly traded healthcare companies to do so [1][3] - The initiative is backed by a $50 million Equity Line of Credit (ELOC) to enhance liquidity and financial infrastructure within its healthcare network [2] Company Strategy - The company aims to disrupt traditional healthcare systems by connecting manufacturers directly to pharmacies and patients, thereby increasing speed, liquidity, and transparency [3] - Wellgistics Health believes that the future of healthcare will favor companies with efficient platforms rather than those with large physical infrastructures [3] XRP Integration Benefits - The integration of XRP is expected to facilitate faster vendor payments, performance-based rebates, and liquidity tools for pharmacies and manufacturers [4] - XRP transactions settle in 3-5 seconds, significantly faster than traditional methods, and cost less than $0.0002 per transfer, compared to $10-$30 for standard bank wires [7] Market Trends - XRP is gaining traction among global institutions, with CME Group set to launch cash-settled XRP futures in May 2025 to meet institutional demand [6] - Mastercard has identified XRP as a bridge currency for cross-border payments, highlighting its efficiency and cost-effectiveness [7] Company Overview - Wellgistics Health operates across pharmaceutical distribution, prescription technology, and clinical fulfillment, connecting over 150 manufacturers to more than 6,000 independent pharmacies [9] - The company provides real-time prescription hub services and aims to eliminate friction in the supply chain, enhancing reimbursement processes and creating transparent pathways [10]

Core Insights - Wellgistics Health, Inc. is launching an initiative to utilize XRP as a treasury reserve and real-time payments infrastructure, aiming to be among the first publicly traded healthcare companies to do so [1][3] - The initiative is backed by a $50 million Equity Line of Credit (ELOC) to enhance liquidity and financial infrastructure across its healthcare network [2] Company Strategy - The company aims to disrupt traditional healthcare systems by connecting manufacturers directly to pharmacies and patients, thereby increasing speed, liquidity, and transparency [3] - Wellgistics Health believes that the future of healthcare will favor companies with efficient platforms rather than those with large physical infrastructures [3] XRP Integration Benefits - The integration of XRP is expected to facilitate faster vendor payments, performance-based rebates, and liquidity tools for pharmacies and manufacturers [4] - XRP transactions settle in 3-5 seconds, significantly faster than traditional methods, and cost less than $0.0002 per transfer, enhancing operational efficiency [7] Market Positioning - Wellgistics Health is positioning itself to lead in the healthcare and fintech convergence by leveraging XRP, as evidenced by the growing institutional interest in XRP [6][8] - The company is focused on unlocking capital velocity and running operations more efficiently than its peers in the pharmaceutical infrastructure space [6] Industry Trends - XRP is gaining traction with major institutions, including the CME Group launching XRP futures and Mastercard identifying XRP as a bridge currency for cross-border payments [6][7] - Ripple's recent acquisitions and regulatory advancements further solidify XRP's role in the financial services landscape [8] Company Overview - Wellgistics Health operates in pharmaceutical distribution, prescription technology, and clinical fulfillment, connecting over 150 manufacturers to more than 6,000 independent pharmacies [9] - The company provides real-time prescription services and aims to streamline the medication supply chain by reducing friction and accelerating reimbursements [10]

Cencora (COR) is slated to report second-quarter fiscal 2025 results on May 7, before market open. In the last reported quarter, the company delivered an earnings surprise of 6.57%. COR's earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 4.94%.(Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.) Q2 Estimates The Zacks Consensus Estimate for revenues is pegged at $74.82 billion, up 9.4% from the prior-year quarter's level. The consensus ma ...

Q3 FY25 Earnings Cardinal Health, Inc. May 1, 2025 © 2025 Cardinal Health. All Rights Reserved. 1 © 2025 Cardinal Health. All Rights Reserved. • Q3 FY25 Earnings Cautions Concerning Forward-Looking Statements Q3 Results © 2025 Cardinal Health. All Rights Reserved. 3 © 2025 Cardinal Health. All Rights Reserved. • Q3 FY25 Earnings This presentation contains forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. These st ...